Search - tctmd.com

Displaying 21 - 40 of 63

Sort: Relevancy | Date

News Conference News ACC 2022

Tricuspid Repair With Pascal Safe, Effective at 1 Year: CLASP TR

Yael L. Maxwell

April 05, 2022

News Conference News ACC 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Michael O'Riordan

April 04, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Shelley Wood

March 28, 2022

News Conference News ACC 2021

‘Enormous’ QoL Improvements With Mavacamten in HCM

Shelley Wood

May 15, 2021

News Conference News ACC 2020

Early Data Support TAVR in Bicuspid Valves, but Questions Remain

Michael O'Riordan

March 29, 2020

News Conference News ACC 2020

PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients

Yael L. Maxwell

March 29, 2020

News Conference News ACC 2020

UK TAVI: Real-world TAVR and SAVR Have Similar 1-Year Mortality

L.A. McKeown

March 29, 2020

News Conference News ACC 2020

Hospital MV Surgical Volume Not Tied to TMVr Outcomes

Todd Neale

March 19, 2020

News Daily News ACC 2020

Better QoL After MitraClip Plus Fewer Deaths, HF Hospitalizations: COAPT

Shelley Wood

March 17, 2020

Presentation ACC 2019

Health Status after Transcatheter Mitral- Valve Repair in Patients with Heart Failure and Secondary Mitral Regurgitation: Results from the COAPT Trial

Presenter: Suzanne V. Arnold

March 18, 2019

News Conference News ACC 2019

COAPT Quality-of-Life Analysis Points to Significant, Sustained Benefits in Health Status With MitraClip

Shelley Wood

March 17, 2019

News Conference News ACC 2019

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

Michael O'Riordan

March 17, 2019

Presentation ACC 2019

Heart Failure and Secondary Mitral Regurgitation: Echocardiographic Outcomes from the COAPT trial

Presenter: Federico M. Asch

March 17, 2019

News Conference News ACC 2019

COAPT Echo Substudy in HF Patients With Mitral Regurgitation Offers New Answers, and More Questions

Shelley Wood

March 17, 2019

News Conference News ACC 2019

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

Shelley Wood

March 11, 2019

News Conference News ACC 2018

Urgent/Emergent TAVR: Risky but Rewarding, TVT Registry Data Hint

Caitlin E. Cox

March 19, 2018

News Conference News ACC 2018

NOTION: 5-Year Outcomes for TAVR Match SAVR in Low-Risk Patients

Shelley Wood

March 10, 2018

News Conference News ACC 2017

MitraClip Commercial Experience at 1 Year Sheds Light on Progress and Lingering Concerns

L.A. McKeown

March 27, 2017

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Todd Neale

March 17, 2017

Advertisement

Tricuspid Repair With Pascal Safe, Effective at 1 Year: CLASP TR

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

What’s Going to Be Hot at ACC 2022, In Person or Virtual

‘Enormous’ QoL Improvements With Mavacamten in HCM

Early Data Support TAVR in Bicuspid Valves, but Questions Remain

PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients

UK TAVI: Real-world TAVR and SAVR Have Similar 1-Year Mortality

Hospital MV Surgical Volume Not Tied to TMVr Outcomes

Better QoL After MitraClip Plus Fewer Deaths, HF Hospitalizations: COAPT

Health Status after Transcatheter Mitral- Valve Repair in Patients with Heart Failure and Secondary Mitral Regurgitation: Results from the COAPT Trial

COAPT Quality-of-Life Analysis Points to Significant, Sustained Benefits in Health Status With MitraClip

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

Heart Failure and Secondary Mitral Regurgitation: Echocardiographic Outcomes from the COAPT trial

COAPT Echo Substudy in HF Patients With Mitral Regurgitation Offers New Answers, and More Questions

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

Urgent/Emergent TAVR: Risky but Rewarding, TVT Registry Data Hint

NOTION: 5-Year Outcomes for TAVR Match SAVR in Low-Risk Patients

MitraClip Commercial Experience at 1 Year Sheds Light on Progress and Lingering Concerns

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content